SG11201906525SA - Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) - Google Patents
Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)Info
- Publication number
- SG11201906525SA SG11201906525SA SG11201906525SA SG11201906525SA SG11201906525SA SG 11201906525S A SG11201906525S A SG 11201906525SA SG 11201906525S A SG11201906525S A SG 11201906525SA SG 11201906525S A SG11201906525S A SG 11201906525SA SG 11201906525S A SG11201906525S A SG 11201906525SA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- thousand oaks
- glp
- oaks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT o mono °nolo Ho Ho lio imio oimIE (10) International Publication Number WO 2018/136440 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61P 3/10 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/013918 (22) International Filing Date: 16 January 2018 (16.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/447,332 17 January 2017 (17.01.2017) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320 (US). (72) Inventors: CHENG, Yuan; 5329 Via Jacinto, New- bury Park, California 91320 (US). NETIROJJANAKUL, Chawita; 4631 Kester Ave., Apt. 103, Sherman Oaks, Cali- fornia 91403 (US). HOLDER, Jerry Ryan; 1102 Waltham Road, Simi Valley, California 93065 (US). WU, Bin; 3090 Hollycrest Avenue, Thousand Oaks, California 91362 (US). FALSEY, James R.; 13209 Peach Hill Road, Moor- park, California 93021 (US). HERBERICH, Bradley J.; 1746 Hays Drive, Newbury Park, California 91320 (US). SHAM, Kelvin; 3111 La Casa Court, Thousand Oaks, Cal- ifornia 91362 (US). MIRANDA, Leslie P.; 3586 Maple- knoll Place, Thousand Oaks, California 91362 (US). LU, Shu-Chen; 2356 Rutland Place, Thousand Oaks, Califor- nia 91362 (US). VENIANT-ELLISON, Murielle M.; 645 Camino Manzanas, Thousand Oaks, California 91360 (US). STANISLAUS, Shanaka; 4196 Minnecota Drive, Thou- sand Oaks, California 91360 (US). YIE, Junming; 4 Sugar- wood Way, Warren, New Jersey 07059 (US). XU, Jing; 67 Bishops Forest Drive, Waltham, Massachusetts 02452 (US). (74) Agent: DERMOTT, Jonathan M. et al.; One Amgen Cen- ter Drive, Patent Operations, MS-35-1-B, Thousand Oaks, California 91320 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 136 440 Al (54) Title: METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) (57) : Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447332P | 2017-01-17 | 2017-01-17 | |
PCT/US2018/013918 WO2018136440A1 (en) | 2017-01-17 | 2018-01-16 | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906525SA true SG11201906525SA (en) | 2019-08-27 |
Family
ID=61832572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906525SA SG11201906525SA (en) | 2017-01-17 | 2018-01-16 | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
Country Status (25)
Country | Link |
---|---|
US (2) | US10905772B2 (en) |
EP (1) | EP3570885A1 (en) |
JP (2) | JP7175899B2 (en) |
KR (1) | KR20190104158A (en) |
CN (1) | CN110662558B (en) |
AR (1) | AR110751A1 (en) |
AU (1) | AU2018210858A1 (en) |
BR (1) | BR112019014588A2 (en) |
CA (1) | CA3049023A1 (en) |
CL (1) | CL2019001963A1 (en) |
CO (1) | CO2019007685A2 (en) |
CR (2) | CR20190380A (en) |
EA (1) | EA201991721A1 (en) |
IL (1) | IL267660A (en) |
JO (1) | JOP20190177A1 (en) |
MA (1) | MA47314A (en) |
MX (1) | MX2019008462A (en) |
NZ (1) | NZ754937A (en) |
PE (1) | PE20191467A1 (en) |
PH (1) | PH12019501656A1 (en) |
SA (1) | SA519402246B1 (en) |
SG (1) | SG11201906525SA (en) |
TW (1) | TWI708613B (en) |
UY (1) | UY37568A (en) |
WO (1) | WO2018136440A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ743474A (en) | 2015-12-23 | 2023-03-31 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JOP20190177A1 (en) | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
AU2018288852A1 (en) * | 2017-06-21 | 2020-01-02 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins |
MX2020001327A (en) * | 2017-08-04 | 2020-03-20 | Amgen Inc | Method of conjugation of cys-mabs. |
US20220152154A1 (en) | 2019-03-08 | 2022-05-19 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
CN112521501A (en) * | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein thereof with GLP-1, and pharmaceutical composition and application thereof |
WO2022056494A1 (en) * | 2020-09-14 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
AU2022276998A1 (en) | 2021-05-21 | 2023-12-07 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
CA3221655A1 (en) * | 2021-06-09 | 2022-12-15 | Swiftnovo Therapeutics Inc. | Therapeutics and methods for treating or ameliorating metabolic disorders |
WO2023173132A1 (en) * | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
CN117659189A (en) * | 2022-09-08 | 2024-03-08 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein thereof with FGF21, and pharmaceutical composition and application thereof |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
JP3068180B2 (en) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | Generation of heterologous antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0575319T3 (en) | 1991-03-11 | 2000-07-10 | Univ Georgia Res Found | Cloning and expression of Renilla luciferase |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
JPH06508880A (en) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | Thermotropic liquid crystal segmented block copolymer |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
ES2301158T3 (en) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | XENOGENIC ANTIBODY PRODUCTION. |
WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
ATE493998T1 (en) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION CONTAINING AN EXENDIN-4 PEPTIDE |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
KR20080059467A (en) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
US7091183B1 (en) | 1996-12-03 | 2006-08-15 | Boston Medical Center Corporation | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
IL129767A0 (en) | 1996-12-12 | 2000-02-29 | Prolume Ltd | Apparatus and method for detecting and identifying infectious agents |
ATE304864T1 (en) | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD INTAKE |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
JP2001513512A (en) | 1997-08-08 | 2001-09-04 | アミリン・ファーマシューティカルズ,インコーポレイテッド | New exendin agonist compounds |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
DE69839021T3 (en) | 1997-11-14 | 2013-08-08 | Amylin Pharmaceuticals, Llc | NOVEL EXENDIN AGONISTS |
US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
DE69838916T2 (en) | 1997-11-14 | 2008-12-18 | Amylin Pharmaceuticals, Inc., San Diego | NOVEL EXENDIN AGONISTS |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
AU759058C (en) | 1998-02-13 | 2005-09-15 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US6232107B1 (en) | 1998-03-27 | 2001-05-15 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
CZ303120B6 (en) | 1998-12-07 | 2012-04-11 | Societe De Conseils De Recherches Et Dapplications Scientifiques S. A. | Compound and pharmaceutical composition |
CA2358107C (en) | 1998-12-22 | 2011-08-23 | Eli Lilly And Company | Shelf-stable formulation of glucagon-like peptide-1 |
PT1140145E (en) | 1999-01-14 | 2005-11-30 | Amylin Pharmaceuticals Inc | NEW FORMULATIONS OF EXENDINA AGONISTS AND METHODS FOR ITS ADMINISTRATION |
EP1143989B1 (en) | 1999-01-14 | 2006-12-13 | Amylin Pharmaceuticals, Inc. | Exendins for glucagon suppression |
US20030087820A1 (en) | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
DK1171465T3 (en) | 1999-03-29 | 2004-12-13 | Uutech Ltd | Analogues to gastroinhibitory peptide and their use in the treatment of diabetes |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
CA2396157A1 (en) | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
DK1257577T3 (en) | 2000-01-27 | 2004-08-02 | Lilly Co Eli | Process for dissolving glucagon as peptide compound |
AU5675701A (en) | 2000-05-16 | 2001-11-26 | Sanwa Kagaku Kenkyusho Co | Agents for preventing or ameliorating insulin resistance and/or obesity |
IL158419A0 (en) | 2001-04-19 | 2004-05-12 | Scripps Research Inst | Methods and composition for the production of orthoganal trna-aminoacyl trna synthetase pairs |
US20050159379A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA) |
JP4566459B2 (en) | 2001-06-07 | 2010-10-20 | 株式会社日立製作所 | Display device |
CN1332711C (en) | 2002-02-20 | 2007-08-22 | 埃米球科技有限公司 | Method for administering GLP-1 molecules |
JPWO2003097031A1 (en) | 2002-05-22 | 2005-09-15 | 株式会社三和化学研究所 | An agent for preventing or improving obesity comprising a methylidene hydrazide compound as an active ingredient |
US20040029805A1 (en) | 2002-06-15 | 2004-02-12 | Wolfe M. Michael | Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP) |
JP2006213598A (en) | 2003-03-19 | 2006-08-17 | Sanwa Kagaku Kenkyusho Co Ltd | Pyrazolopyrimidine compound and use of the same |
CN101974090B (en) | 2003-06-12 | 2015-06-17 | 伊莱利利公司 | GLP-1 analog fusion proteins |
WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
EP2417980A1 (en) | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US7991890B2 (en) | 2004-09-30 | 2011-08-02 | Microsoft Corporation | Game console communication with a device |
EP1809335A2 (en) | 2004-10-25 | 2007-07-25 | Cytos Biotechnology AG | Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof |
EP1831252B1 (en) | 2004-12-22 | 2009-07-01 | Eli Lilly And Company | Glp-1 analog fusion protein formulations |
US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
MX2007009760A (en) | 2005-02-11 | 2007-11-07 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties. |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
WO2006119905A1 (en) | 2005-05-11 | 2006-11-16 | Sanofi-Aventis | Use of a gip promoter polymorphism |
WO2006125763A1 (en) | 2005-05-25 | 2006-11-30 | Novo Nordisk A/S | Stabilized polypeptide formulations |
CA2622069A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
US20090186817A1 (en) | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
WO2008006113A2 (en) | 2006-07-07 | 2008-01-10 | The Texas A & M University System | Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis |
WO2008019143A2 (en) | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc | Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
CA2660835A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable propperties |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
US20090144162A1 (en) | 2007-11-29 | 2009-06-04 | Neil Milne | Transaction Security Method and Apparatus |
GB0814068D0 (en) | 2008-08-01 | 2008-09-10 | Univ Ulster | Active immunisation against GIP |
CA2733006A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal |
AU2009280012B2 (en) | 2008-08-07 | 2012-12-06 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
WO2010016936A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
CN103641906A (en) | 2008-08-07 | 2014-03-19 | 益普生制药股份有限公司 | Glucose-dependent insulinotropic polypeptide analogues |
WO2010016940A2 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
US20120157379A1 (en) | 2009-07-31 | 2012-06-21 | Sheau Yu Hsu | Gastric Inhibitory Peptide Variants and Their Uses |
RU2012136450A (en) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
SG191194A1 (en) | 2010-12-22 | 2013-07-31 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
EP2685257A4 (en) | 2011-03-08 | 2014-10-01 | Sanwa Kagaku Kenkyusho Co | Analysis method |
KR102002783B1 (en) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
US20160185837A1 (en) | 2013-08-16 | 2016-06-30 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
CA2932325A1 (en) * | 2013-12-04 | 2015-06-11 | Innovative Targeting Solutions Inc. | G-protein coupled receptor agonists and methods |
EP3079722B1 (en) | 2013-12-13 | 2021-03-24 | Novo Nordisk Health Care AG | Method for thioether conjugation of proteins |
MX2016008102A (en) | 2013-12-17 | 2017-05-12 | The Metrohealth System | Compositions and methods for treating fatty tissue buildup. |
TWI622596B (en) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | Glucagon receptor agonists |
NZ743474A (en) * | 2015-12-23 | 2023-03-31 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JOP20190177A1 (en) | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
-
2017
- 2017-06-16 JO JOP/2019/0177A patent/JOP20190177A1/en unknown
-
2018
- 2018-01-16 CA CA3049023A patent/CA3049023A1/en active Pending
- 2018-01-16 US US15/872,841 patent/US10905772B2/en active Active
- 2018-01-16 CR CR20190380A patent/CR20190380A/en unknown
- 2018-01-16 JP JP2019538424A patent/JP7175899B2/en active Active
- 2018-01-16 CR CR20230302A patent/CR20230302A/en unknown
- 2018-01-16 MA MA047314A patent/MA47314A/en unknown
- 2018-01-16 CN CN201880005883.1A patent/CN110662558B/en active Active
- 2018-01-16 SG SG11201906525SA patent/SG11201906525SA/en unknown
- 2018-01-16 EP EP18714635.2A patent/EP3570885A1/en active Pending
- 2018-01-16 PE PE2019001431A patent/PE20191467A1/en unknown
- 2018-01-16 NZ NZ754937A patent/NZ754937A/en unknown
- 2018-01-16 AU AU2018210858A patent/AU2018210858A1/en active Pending
- 2018-01-16 UY UY0001037568A patent/UY37568A/en unknown
- 2018-01-16 KR KR1020197020599A patent/KR20190104158A/en not_active Application Discontinuation
- 2018-01-16 AR ARP180100097A patent/AR110751A1/en unknown
- 2018-01-16 WO PCT/US2018/013918 patent/WO2018136440A1/en unknown
- 2018-01-16 MX MX2019008462A patent/MX2019008462A/en unknown
- 2018-01-16 BR BR112019014588-5A patent/BR112019014588A2/en unknown
- 2018-01-16 EA EA201991721A patent/EA201991721A1/en unknown
- 2018-01-17 TW TW107101643A patent/TWI708613B/en active
-
2019
- 2019-06-26 IL IL267660A patent/IL267660A/en unknown
- 2019-07-12 CL CL2019001963A patent/CL2019001963A1/en unknown
- 2019-07-16 PH PH12019501656A patent/PH12019501656A1/en unknown
- 2019-07-17 CO CONC2019/0007685A patent/CO2019007685A2/en unknown
- 2019-07-17 SA SA519402246A patent/SA519402246B1/en unknown
-
2021
- 2021-01-15 US US17/151,045 patent/US20210154318A1/en active Pending
-
2022
- 2022-09-07 JP JP2022141970A patent/JP2022184880A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210154318A1 (en) | 2021-05-27 |
SA519402246B1 (en) | 2023-02-15 |
CL2019001963A1 (en) | 2020-04-03 |
CR20190380A (en) | 2019-11-07 |
CN110662558B (en) | 2024-04-09 |
MA47314A (en) | 2019-11-27 |
US10905772B2 (en) | 2021-02-02 |
EP3570885A1 (en) | 2019-11-27 |
TWI708613B (en) | 2020-11-01 |
NZ754937A (en) | 2023-04-28 |
US20180311372A1 (en) | 2018-11-01 |
BR112019014588A2 (en) | 2020-02-18 |
KR20190104158A (en) | 2019-09-06 |
TW201838648A (en) | 2018-11-01 |
MX2019008462A (en) | 2019-11-21 |
JP2022184880A (en) | 2022-12-13 |
CO2019007685A2 (en) | 2019-07-31 |
CR20230302A (en) | 2023-08-25 |
JOP20190177A1 (en) | 2019-07-16 |
JP2020506900A (en) | 2020-03-05 |
AU2018210858A1 (en) | 2019-07-18 |
WO2018136440A1 (en) | 2018-07-26 |
EA201991721A1 (en) | 2020-04-08 |
CN110662558A (en) | 2020-01-07 |
CA3049023A1 (en) | 2018-07-26 |
AR110751A1 (en) | 2019-05-02 |
UY37568A (en) | 2018-07-31 |
PH12019501656A1 (en) | 2019-10-28 |
IL267660A (en) | 2019-08-29 |
JP7175899B2 (en) | 2022-11-21 |
PE20191467A1 (en) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906525SA (en) | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201805255TA (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
SG11201906229QA (en) | Anti-ccr7 antibody drug conjugates | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders |